Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies
Authors' conclusion
Observational data from population-based studies suggest that GLDs such as SGLT2is are associated with beneficial long-term liver-related outcomes in T2D patients with NAFLD. Additional studies, including randomized controlled trials with long-term follow-up, are needed to confirm these findings.
Study context
- Population
- Individuals with T2D and no liver disease other than non-alcoholic fatty liver disease (NAFLD); PubMed, Web of Science and Embase searched from inception to 23 February 2024
- Participants
- 1,274,641 individuals10 cohort studies
- Comparison
- Glucose-lowering drugs and liver-related outcomes
- Outcome
- Liver-related outcomes
- Follow-up
- Median ranged from 8.9 to 76 months
Pooled result
As reported in the abstract
- SGLT2is associated with the strongest reduction in NAFLD incidence, cirrhosis and composite liver-related events vs other medications
- TZDs associated with reduced risk of NAFLD and cirrhosis; not significantly associated with lower hepatocellular carcinoma incidence
- GLP-1 RAs significantly associated with reduced liver-related mortality
Original publication
Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies. Diabet Med. Published 28 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →